Patent · US Active

Antiviral agents for amantadine-resistant influenza A

US10676428B2 · kind B2 · utility

0Cited by
5References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 19, 2016
Grant dateJun 9, 2020
Priority date
Expiry dateDec 19, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C311/29
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.